873054-97-8 Usage
General Description
4-Hydroxy-5-methoxyquinoline-3-carboxylic acid is a chemical compound with the molecular formula C11H9NO5. It is a derivative of quinoline and contains a hydroxy group and a methoxy group. 4-Hydroxy-5-methoxyquinoline- 3-carboxylic acid has been studied for its potential pharmacological properties, including its ability to act as an anti-inflammatory and antioxidant agent. It has also been investigated for its potential as a chelating agent in metal ion coordination chemistry. In addition, 4-Hydroxy-5-methoxyquinoline-3-carboxylic acid has been used as a building block for the synthesis of other chemical compounds with potential biological activities. Overall, this compound has demonstrated potential for various applications in the fields of medicine and chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 873054-97-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,0,5 and 4 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 873054-97:
(8*8)+(7*7)+(6*3)+(5*0)+(4*5)+(3*4)+(2*9)+(1*7)=188
188 % 10 = 8
So 873054-97-8 is a valid CAS Registry Number.
InChI:InChI=1/C11H9NO4/c1-16-8-4-2-3-7-9(8)10(13)6(5-12-7)11(14)15/h2-5H,1H3,(H,12,13)(H,14,15)
873054-97-8Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 0359, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
